Eruptive halo nevi and new-onset vitiligo post-COVID-19 infection

Pastukhova, Elena; Ghazawi, F.M.

doi:10.1016/j.jdcr.2023.01.030

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, COVID-19 disrupts immune tolerance, resulting in increased inflammation potentiated by increased interferon gamma (IFN-γ) signaling and consequent cytotoxic destruction of melanocytes. 11 Furthermore, Schmidt et al postulated a hyperstimulated CD8+ response and increased oxidative stress as catalysts. 12 Finally, based on the shift of the immune system in non-segmental vitiligo toward adaptive type 1 (IFN-γ and CD8+T cells) and innate immune responses, immune activation during SARS-CoV-2 infection or COVID-19 disease may increase vitiligo disease activity.…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 Vaccine and COVID-19 Infection on Vitiligo Activity and Progression

Shi,

Sun,

Ding

2023

CCID

View full text Add to dashboard Cite

Background Coronavirus disease 2019 (COVID-19) has given rise to several new onset or exacerbated dermatologic disorders including vitiligo. However, the relationship between COVID-19 infection or its associated vaccines and vitiligo progression is unclear. Aim We investigate the impact of COVID-19 infection and its associated vaccines on vitiligo progression. Methods A cross-sectional study was performed among patients who visited Department of Dermatology, Peking University People’s Hospital between 2022.1 and 2023.6. Detailed information including demographic characteristics, vitiligo clinical features, information on COVID-19 infection and vaccination and disease progression was collected by an electronic questionnaire. Results Overall, 314 patients with vitiligo completed the questionnaire. 47.5% were males, with an average age of 25.5±15.9 years. 266 (84.7%) patients had received COVID-19 vaccination, and 70.3% of the patients reported progression of vitiligo after vaccination, mostly within 3 months. 55.6% of the patients had disease progression after the second dose of vaccine. 270 patients experienced COVID-19 infection, and 30.7% of these patients had progression of vitiligo after infection, most of the progression occurred within 1–2 months. 184 patients (68.2%) interrupted treatment. Analysis results indicated patients in active stage had a higher risk for vitiligo progression after COVID-19 infection and vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%